Delving into the Latest Updates on Guangzhou Curegenix Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

PORCN(Protein-serine O-palmitoleoyltransferase porcupine)	1

主要目的：评价口服CGX1321在晚期胃肠道癌症（包括伴有Rspo2、Rspo3和RNF43基因突变的胃肠道癌症）患者的安全性和耐受性；确定剂量限制性毒性（DLT）及最大耐受剂量（MTD）和／或临床2期研究推荐剂量（RP2D）；进一步评价在证实有WNT信号通路上游基因（例如，Rspo2、Rspo3或RNF43）改变的组织学诊断的GI肿瘤受试者中，在MTD和／或RP2D剂量下，CGX1321的安全性和耐受性（扩大研究阶段）。

[Translation]

Primary objectives: To evaluate the safety and tolerability of oral CGX1321 in patients with advanced gastrointestinal cancer (including gastrointestinal cancer with Rspo2, Rspo3 and RNF43 gene mutations); to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) and/or the recommended dose (RP2D) for Phase 2 clinical studies; to further evaluate the safety and tolerability of CGX1321 at the MTD and/or RP2D doses in subjects with histologically diagnosed GI tumors with confirmed alterations in genes upstream of the WNT signaling pathway (e.g., Rspo2, Rspo3 or RNF43) (expansion study phase).

Start Date-

Sponsor / Collaborator

Guangzhou Curegenix Ltd.

NCT03507998

/ Unknown statusPhase 1

A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.

Start Date17 Jun 2017

Sponsor / Collaborator

Curegenix, Inc.

[+1]

100 Clinical Results associated with Guangzhou Curegenix Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou Curegenix Ltd.

Login to view more data

100 Deals associated with Guangzhou Curegenix Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou Curegenix Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data